Search

Acupath LABORATORIES INC., Biomarkers, Bladder Cancer, Business, Cancer, Cancer Biomarkers, Carcinoma Biomarkers, Cytology, Diagnostics and Screening, Health and Medicine, Oncology, Risk and Prevention Keywords: Acupath LABORATORIES INC.; Biomarkers; Bladder Cancer; Business; Cancer; Cancer Biomarkers; Carcinoma Biomarkers; Cytology; Diagnostics and Screening; Health and Medicine; Oncology; Risk and Prevention EN Acupath LABORATORIES INC. Biomarkers Bladder Cancer Business Cancer Cancer Biomarkers Carcinoma Biomarkers Cytology Diagnostics and Screening Health and Medicine Oncology Risk and Prevention 69 69 1 09/19/23 20230919 NES 230919 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Acupath Labs released a white paper highlighting the impressive results of a large-scale internal study analyzing the clinical utility of its Acu-UR017 bladder cancer biomarker. [Extracted from the article]

A new editorial paper published in Oncotarget discusses acute myeloid leukemia (AML), a type of aggressive cancer. The paper highlights recent advancements in understanding AML biology and the potential for developing novel drug therapies. The researchers suggest exploring reductive carboxylation as a possible drug target to weaken tumor cell survival mechanisms and improve patient outcomes. The paper provides further information on this topic and can be accessed through the provided DOI link. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the therapeutic potential and challenges of cytostatic persister cancer cells. These cells are able to remain viable despite treatment and can contribute to residual diseases and the emergence of resistant clones and relapses. Unlike resistant cells, persister cancer cells enter a non-proliferating state that is reversible upon treatment discontinuation. The paper highlights the need to understand the properties of cytostatic persisters and explores strategies for targeting them to reduce cancer recurrence. The researchers suggest that administering multiple targeted regimens may be necessary to effectively deplete the persister reservoirs in patients undergoing cancer treatments. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the molecular functions of regulatory genetic variants associated with cancer. The paper highlights the challenges in understanding the effects of genetic variants, such as their small effect size and their location in non-protein-coding regions of the genome. The researchers propose integrating genomic, epigenomic, transcriptomic, and machine learning methods to identify functional genetic variants and characterize their mode of action in regulating target genes. This approach has implications for cancer research and precision medicine. [Extracted from the article]

A research paper published in Oncotarget's Volume 15 discusses the differential expression of the Mad2 gene in human esophageal cancer. The study focuses on the relationship between the consumption of raw areca nut and the development of esophageal squamous cell carcinoma (ESCC). The researchers found that Mad2 expression levels were both overexpressed and underexpressed in the samples, leading to premature anaphase and chromosome missegregation. The study suggests that Mad2 expression levels, along with chromosomal abnormalities, could serve as a clinical biomarker for esophageal cancer. Further research is needed to understand the role of the pRb-E2F1 circuit in Mad2 down-regulation. [Extracted from the article]

A new report from researchers at the Department of Artificial Intelligence in Valencia, Spain explores the effects of color normalization (CN) on Content-Based Histopathological Image Retrieval (CBHIR) in the context of breast cancer diagnosis. CBHIR is a search technique that uses visual content and histopathological features of whole-slide images to assist pathologists in diagnosing cancer. The study found that using CN as a pre-processing step improved the accuracy of the CBHIR framework by 14%, reaching an accuracy of 97% compared to working with the original images. This research has important implications for improving the performance of CBHIR tools in hospitals with varying staining protocols. [Extracted from the article]

A recent study conducted in Finland aimed to determine the frequency of NTRK gene fusion in patients with papillary thyroid cancer (PTC). The researchers identified patients with PTC from Finland's Auria Biobank and analyzed their genetic alterations, clinical characteristics, disease progression, and treatment pathways. The study found that NTRK gene fusion was infrequent in PTC patients, with only 1.5% of patients having the fusion. The study also demonstrated the feasibility of linking biobank samples to electronic health records to describe patient characteristics and outcomes. [Extracted from the article]

A new study from Amrita Vishwa Vidyapeetham in Kerala, India explores the challenges faced during implant-assisted prosthetic rehabilitation in fibula reconstructed jaws for head and neck cancer patients. The study aims to gather evidence on the difficulties and corrective measures in prosthetic rehabilitation for this population. The researchers will conduct a scoping review using the Joanna Briggs Institute protocol and will search databases such as PubMed, Scopus, and Google Scholar for relevant articles published in the past 20 years. The findings will contribute to improving prosthetic treatment care for individuals with fibula-reconstructed head and neck cancer. [Extracted from the article]

A recent report from Pfizer Research & Development discusses the analysis of longitudinal data in the context of bladder cancer. The researchers developed a Bayesian Bernoulli-Exponential model to account for varying visit times and unbalanced data. Through statistical simulations, they assessed the model's performance and found that it performed better for smaller sample sizes and less varying time sequences. The application of the model to bladder cancer recurrence data revealed a significant effect of prior tumor recurrence on the probability of subsequent recurrences. For more information, readers can refer to the original article published in BMC Medical Research Methodology. [Extracted from the article]

A patent has been issued for an endcap for a liquid medicine-injecting tube. The endcap is designed to reduce the loss of liquid medicine during the priming process and allows medical staff to easily check if the priming has been completed. The endcap includes a flow passage, a filter member to remove air from the liquid medicine, a liquid-absorbing member, and an indicator that changes color when the air is discharged. The invention aims to improve the efficiency and safety of injecting liquid medicine into patients. The patent was filed by inventor Yong Hyun Kim and assigned to E-Wha Meditech Inc. [Extracted from the article]

A recent study conducted in Valencia, Spain, highlights the potential of an unsupervised Convolutional Auto Encoder (CAE) approach in improving the accuracy and efficiency of cancer diagnosis. The study focuses on Content-Based Medical Image Retrieval (CBMIR), which allows pathologists to search for similar histopathological Whole Slide Images (WSIs) to enhance diagnostic reliability. The customized CAE, known as Unsupervised CBMIR (UCBMIR), was evaluated using various techniques and achieved high recall and precision rates. The tool also demonstrated the ability to identify diverse patterns and retrieve images with the same cancer type. This research offers a promising step towards more transparent and accurate cancer diagnosis. [Extracted from the article]

A research perspective published in Oncotarget's Volume 14 discusses the relationship between melatonin and carcinogenesis in mice. The study highlights the inhibitory effect of melatonin on cancer in vivo, specifically on transplantable mammary tumors in mice. It also demonstrates that melatonin administration at night inhibits chemically induced mammary carcinogenesis in mice and rats. The researchers emphasize the importance of timing in melatonin administration for its applications in oncology. The study provides valuable insights into the effects of melatonin on cancer in mice and highlights the need for further research in this area. [Extracted from the article]

Smylio Inc. has filed a patent application for a saliva collection and testing system that aims to monitor patient wellness by collecting saliva samples over time. These samples can provide biomarkers for diseases like cancer and cardiovascular disease. The system includes a saliva analysis engine and a health monitoring engine to update the patient's health profile. Additionally, the article explores the potential benefits of using virtual reality (VR) technology in healthcare, such as pain management, rehabilitation, and mental health treatment. It also acknowledges the challenges and limitations of implementing VR in healthcare, including cost and accessibility, while emphasizing the need for further research and development in this area. [Extracted from the article]

A patent has been issued to Videra Surgical Inc. for a fiducial marker that can be used in oncological and other procedures. The marker is designed to help radiation oncologists accurately visualize the extent of the tumor bed after surgery, allowing for more precise targeting of radiation therapy. The marker consists of a flexible radiopaque filament that can be placed at the target tissue and observed under radiographic imaging. It can be used in various surgical procedures and is particularly useful in cases where a seroma, a fluid-filled pocket that can form after surgery, may not accurately represent the true tumor bed size and location. The marker can also be coated to enhance observation and prevent migration. [Extracted from the article]

Keywords for this news article include: Cancer, Business, Oncology, Natera Inc., Health and Medicine. Business, Cancer, Health and Medicine, Natera Inc., Oncology Keywords: Business; Cancer; Health and Medicine; Natera Inc.; Oncology EN Business Cancer Health and Medicine Natera Inc. Oncology 425 425 1 05/22/23 20230523 NES 230523 2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported financial results for the first quarter ended March 31, 2023. [Extracted from the article]

Keywords: Business; Cancer; Health and Medicine; Healthcare Biotechnology Companies; Investment and Finance; Oncology; Veracyte Inc EN Business Cancer Health and Medicine Healthcare Biotechnology Companies Investment and Finance Oncology Veracyte Inc 1182 1182 1 05/15/23 20230516 NES 230516 2023 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Veracyte, Inc. (Nasdaq: VCYT) announced financial results for the first quarter ended March 31, 2023. Business, Cancer, Health and Medicine, Healthcare Biotechnology Companies, Investment and Finance, Oncology, Veracyte Inc "In addition, we further enhanced our Afirma test, as well as augmented the clinical evidence in support of adoption and reimbursement of our products, ultimately helping to advance our vision of transforming cancer care for patients all over the world.". [Extracted from the article]

A method of computing polygenic risk score (PRS) for a given population using the self-designed SNP chip according to claim 1, comprising steps that are divided into two flows: a first flow computing PRS based on a disease-/trait-related gene database collected from open sources and provided by parties, comprising: using data from the disease-/trait-related gene database collected from open sources and provided by parties; genotypic calling to generate a Variant Call Format (VCF) file; performing imputation, normalization, and annotation on the VCF file to generate a post-processed VCF file; converting the post-processed VCF file to a binary file (bfile), then computing PRS for all samples in the database; and a second flow computing PRS based on test samples, comprising: using genetic data obtained from the test samples; genotype calling to generate a VCF file; performing imputation, normalization, and annotation on the VCF file to generate a post-processed VCF file; converting the post-processed VCF file to a bfile to compute PRS for the test samples; wherein the self-designed SNP chip is used in the VCF file generation stage of both flows; wherein the VCF file is to be subjected to imputation using a given population genomic dataset as a reference and harmonized by using a data harmonization process; wherein the new PRS-computed samples in the second flow are to be added to the existing sample set in the database; data generated from these two computation flows is to be harmonized and input into a machine learning model to form a single computation process to generate PRS for a group of new test samples. The method according to claim 6, wherein the data of the machine learning model is selected from: a PRS parameter; a Genome-Wide Association Studies (GWAS) dataset; a reference sample dataset in the database. [Extracted from the article]

The method comprises receiving first image data, the first image data representing the tissue sample stained with a first staining agent (e.g., H&E); receiving second image data, the second image data representing the tissue sample after washing the tissue sample to remove the first staining agent from the tissue specimen and staining the tissue sample with a second staining agent (e.g., a special stain); registering the first and second image data to generate registration data; receiving data indicating a region of interest represented in the second image data; and determining a mask in the first image data based upon the received data indicating a region of interest represented in the second image data and the registration data. Receiving data indicating a region of interest represented in the first image data may comprise displaying the first and second image data side-by-side. Once the region of interest is identified and mask created in the second image data it can be transferred to the first image data due to the registration of the first and second images. Processing the first image data may comprise processing the first image data using a trained classifier or pattern recognizer. [Extracted from the article]

These include the impact of age on cancer risk, the role played by inherited tumor predisposition syndromes, and the interaction of genetics and environmental exposures on cancer risk." Keywords: Menlo Park; State:California; United States; North and Central America; Business; Cancer; Cancer Risk; Carcinogenesis; Engineering and Scientific Consulting Companies; Environment; Epidemiology; Exponent Inc.; Genetics; Health and Medicine; Malignant Mesothelioma; Mesotheliomas; Oncology; Risk and Prevention EN Menlo Park State:California United States North and Central America Business Cancer Cancer Risk Carcinogenesis Engineering and Scientific Consulting Companies Environment Epidemiology Exponent Inc. Genetics Health and Medicine Malignant Mesothelioma Mesotheliomas Oncology Risk and Prevention 289 289 1 08/07/23 20230808 NES 230808 2023 AUG 8 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Malignant Mesothelioma. [Extracted from the article]

Platform for perpetual clinical collaboration and innovation with patient communication using anonymized electronic health record data, clinical, and patient reported outcomes and data. The platform of claim 1, wherein the patient-facing messaging service of the patient help center allows the patient to send and receive text messages, voice messages, photo messages, video messages, or any combination thereof. [Extracted from the article]

The research technology used in the study leverages a patient-specific panel developed to identify variants from a patient's own tumor rather than a static gene panel. This group of 61 patients included 42 recurrence-free patients and 19 patients who were disease-free at the time the ctDNA was assessed but subsequently developed new primary cancers during follow-up. [Extracted from the article]

Since radiation target/treatment planning is typically performed using x-ray based imaging after the soft tissue has been closed, the imaging often does not delineate the precise location where malignant or otherwise diseased tissue was removed and when radiation therapy to the tumor bed may be required. As a result, benign tissues unnecessarily receive an increased dose of radiation therapy, the area of radiation treatment can be unnecessarily large, and the tumor bed can receive too little radiation therapy. Therefore, the seroma might not represent the true tumor bed size and location, and the seroma might lead a radiation oncologist to inaccurately plan the radiation treatment location and size. [Extracted from the article]

Keywords for this news article include: International Business Machines Corporation (IBM), Cancer, Business, Oncology, Health and Medicine, Technology Companies. Keywords: Business; Cancer; Health and Medicine; Oncology; Technology Companies EN Business Cancer Health and Medicine Oncology Technology Companies 1249 1249 1 03/23/23 20230321 NES 230321 2023 MAR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on cancer are presented in a new report. [Extracted from the article]

A urine analysis method comprising: analyzing urine particles in a urine sample by a urine analyzer; transporting the urine sample to an imaging apparatus; capturing images of the urine sample by the imaging apparatus; displaying an analysis result of the urine sample obtained by the urine analyzer and the captured images of the urine sample captured by the imaging apparatus by a computer connected to the urine analyzer and the imaging apparatus. The urine analysis system according to this aspect includes: a testing apparatus that measures particles included in a urine sample according to a flow cytometry method; an image capturing apparatus that captures images of the urine sample to acquire images of particles in the urine sample; and a management apparatus that receives a measurement result obtained by the testing apparatus and the particle images acquired by the image capturing apparatus. The urine analysis method according to this aspect includes: measuring particles included in a urine sample according to a flow cytometry method; automatically sucking the urine sample based on a measurement result of the particles; capturing images the urine sample to acquire images of particles in the urine sample; and displaying the measurement result obtained by the flow cytometry method and the particle images in a comparable manner. A computer-implemented method comprising: controlling the urine analyzer to analyze urine particles in a urine sample; controlling a transport device to transport the urine sample to an imaging apparatus; controlling the imaging apparatus to capture images of the urine sample; displaying an analysis result of the urine sample obtained by the urine analyzer and the captured images of the urine sample captured by the imaging apparatus. [Extracted from the article]

"In the framework of the EX2TRICAN project, exploring unresolved extreme cancer phenotypes, we applied exome sequencing on rare familial cases with male breast cancer, identifying a novel pathogenic variant of ATR (p.Leu1808)." This work further demonstrates the interest of an extended genetic analysis such as exome sequencing to identify very rare variants that can play a role in cancer predisposition in extreme phenotype cancer cases unexplained by classical cancer gene panels testing. [Extracted from the article]

Keywords: Waltham; State:Massachusetts; United States; North and Central America; Clinical Oncology; Business; Medical Technology Companies; Multinational Companies; Radioisotopes; Tritium EN Waltham State:Massachusetts United States North and Central America Clinical Oncology Business Medical Technology Companies Multinational Companies Radioisotopes Tritium 2023 MAR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Data detailed on Clinical Oncology have been presented. The news reporters obtained a quote from the research from PerkinElmer Health Science Inc., "These suspected substances were termed carcinogens and among those investigated were N-nitrosamines (or simply nitrosamines). [Extracted from the article]